Loading patent…
AssigneeU.S. NUTRACEUTICALS, LLC d/b/a Valensa International
InventorsJohn A. MINATELLI, W. Stephen Hill, Rudi E. Moerck
Estimating the term…
A composition and method of retarding and ameliorating eye diseases and injuries is disclosed. The method comprises administering a synergistic mixture of certain carotenoids, including the carotenoid astaxanthin, with phospholipid and triglyceride bound EPA and DHA derived from omega choline, in which said omega choline contains at least 30% total phospholipids, in a therapeutically effective amount to prevent, retard or treat eye central nervous system diseases or injuries, such as age-related macular degeneration, cataract, dry eye syndrome due to glandular inflammation and other central nervous system degenerative diseases, photic injury, ischemic diseases, and inflammatory diseases.
A composition comprising a therapeutically effective amount of a synergistic multi-ingredient composition of mixed carotenoids including at least S, S′-astaxanthin derived from Haematococcus pluvialis, and one or more of lutein and/or trans-zeaxanthin or meso-zeaxanthin admixed with a therapeutically effective amount of omega choline containing phospholipid bound and triglyceride bound EPA and DHA in which said omega choline contains at least 304 total phospholipids.
A method of treating the eyes of a human or mammal by administrating a therapeutically effective amount of a synergistic multi-ingredient composition of mixed carotenoids including at least S, S′-astaxanthin derived from Haematococcus pluvialis, and one or more of lutein and/or trans-zeaxanthin or meso-zeaxanthin admixed with a therapeutically effective amount of omega choline containing phospholipid bound and triglyceride bound EPA and DHA in which said omega choline contains at least 30% total phospholipids.
A method of preventing retinal damage or retinal disease, including age related macular degeneration, eye strain, accommodative dysfunction of the eye and asthenopia, diabetic retinopathy or ameliorating further damage to a human or mammal suffering from retinal damage or retinal disease including age related macular degeneration, eye strain, accommodative dysfunction of the eye and asthenopia, diabetic retinopathy or dry eye syndrome by administering a therapeutically effective amount of a synergistic multi-ingredient composition of mixed carotenoids including at least S, S′-astaxanthin derived from Haematococcus pluvialis, and one or more of lutein and/or trans-zeaxanthin or meso-zeaxanthin admixed with a therapeutically effective amount of omega choline containing phospholipid bound and triglyceride bound EPA and DHA in which said omega choline contains at least 30% total phospholipids.
Dependencies are inferred from the claim text.